Akeso, Inc. Receives NMPA Approval for Breakthrough Psoriasis Drug Gumokimab (AK111)
Key Points Highlighted from the Announcement
- NMPA Approval Granted: Akeso, Inc. has secured regulatory approval from the National Medical Products Administration (NMPA) of China for gumokimab (AK111), branded as 奇佑康®, for the treatment of moderate-to-severe plaque psoriasis.
- Clinical Trial Success: Approval was based on a pivotal Phase III study (AK111–301) and three supportive clinical trials, all meeting their efficacy endpoints.
- Outstanding Clinical Outcomes:
- Rapid and Potent Effect: At 12 weeks, 94.6% of patients achieved a PASI75 response (significant improvement in symptoms), with 47.7% achieving PASI100 (complete clearance of lesions). These results outperformed comparable drugs targeting the same receptor, which yielded a 28.6% PASI100 rate.
- Sustained Efficacy: At 52 weeks, nearly 100% of patients maintained a PASI75 response, and 68.9% achieved PASI100—again, higher than the 39.2% PASI100 rate for competing therapies.
- Excellent Safety Profile: The incidence of adverse events, including infections, was among the lowest reported among IL-17-inhibitor trials.
- Patient Convenience: Gumokimab requires only 17 injections annually, compared to 34 injections for competing drugs in the same class.
- Pipeline Progress: The drug is also being studied for ankylosing spondylitis, with its application currently under review by Chinese regulators.
Important Information for Shareholders
- Potential Share Price Catalyst: The NMPA approval for gumokimab is a significant milestone for Akeso, Inc., representing its successful entry into China’s rapidly growing autoimmune therapeutics market. This approval could drive future revenues and increase Akeso’s market share in the biologics segment.
- Competitive Differentiation: Gumokimab’s superior efficacy and safety profile, along with its convenient dosing schedule, may enable it to capture market share from established treatments, potentially impacting future sales and profitability.
- Pipeline Value: Progress on gumokimab’s ankylosing spondylitis indication adds further upside potential for the company, with regulatory review underway and clinical endpoints already met.
- Company Leadership: The announcement was issued under the authority of Dr. Xia Yu, Chairwoman and Executive Director, underscoring strong executive support and governance.
Details for Investors
Gumokimab (AK111) is a novel, independently developed humanized monoclonal antibody targeting IL-17, a key cytokine implicated in autoimmune diseases like psoriasis and ankylosing spondylitis. The recent approval for moderate-to-severe plaque psoriasis is based on robust clinical data. The pivotal Phase III trial demonstrated that gumokimab offers rapid, potent, and sustained clearance of psoriatic lesions, with nearly all patients achieving significant improvements after one year of treatment.
Notably, gumokimab’s annual injection burden is half that of other IL-17 inhibitors, providing a significant convenience advantage for patients. The company’s ongoing efforts to expand indications to ankylosing spondylitis could further enhance its commercial prospects.
Given its differentiated clinical profile, strong trial results, and regulatory momentum, this news represents a potentially significant value driver for Akeso, Inc. shareholders.
Disclaimer
The information provided herein is a summary of a corporate announcement and is intended for informational purposes only. It should not be considered investment advice. Investors are advised to conduct their own due diligence and consult with their professional advisors before making investment decisions. The company’s future performance may be affected by various risks and uncertainties, including market conditions, regulatory outcomes, and competition.
Akeso（康方生物）獲中國NMPA批准創新銀屑病新藥Gumokimab (AK111)
重點摘要
- 獲NMPA批准：康方生物（Akeso, Inc.）旗下Gumokimab（AK111，商品名奇佑康®）獲中國國家藥品監督管理局（NMPA）批准，用於治療中重度斑塊狀銀屑病。
- 臨床試驗表現優異：獲批基於一項關鍵三期臨床（AK111–301）及三項支持性研究，全部達到預設療效指標。
- 臨床數據詳情：
- 快速明顯療效：治療12週時，94.6%患者達到PASI75標準，47.7%患者皮損完全清除（PASI100），遠高於同類藥物的28.6%。
- 持續療效：治療52週時，幾乎所有患者（接近100%）保持PASI75，68.9%達到PASI100，亦高於同類藥物的39.2%。
- 安全性良好：治療中不良事件、嚴重不良事件及感染發生率於同類IL-17藥物中屬最低水平之一。
- 用藥便捷：每年僅需注射17次，較同類藥物的34次大幅減少。
- 研發管線進展：Gumokimab同步用於治療強直性脊柱炎的三期註冊研究已達標，相應新藥註冊申請正由NMPA藥審中心審核中。
股東必須關注的事項
- 潛在股價催化劑：Gumokimab獲批意味著康方生物正式進軍中國自身免疫疾病生物藥市場，有助於推動未來收入增長及提升行業地位。
- 市場競爭優勢：該藥在療效、安全性及用藥便捷性上均具明顯優勢，有望搶佔現有治療藥物市場份額，提升盈利能力。
- 管線價值提升：強直性脊柱炎適應症進展順利，若獲批將進一步擴大公司產品組合。
- 公司管理層：此公告由董事會主席兼執行董事夏瑜博士發出，管理層決策能力強。
投資者詳細信息
Gumokimab（AK111）為康方生物自主研發的人源化單抗，靶向IL-17細胞因子，主要用於治療銀屑病及強直性脊柱炎。本次中重度銀屑病獲批基於良好臨床數據，顯示出快速、持久的療效及優異的安全性。該藥年注射次數遠低於同類IL-17抑制劑，患者依從性更高。強直性脊柱炎新適應症正等待審批，未來市場潛力巨大。
憑藉其卓越臨床表現、研發進展及政策紅利，奇佑康®有望成為公司重要業績增長點，屬具股價推動力的利好消息。
免責聲明
本文僅為公司公告內容摘錄及資訊整理，不構成任何投資建議。投資者應自行進行盡職調查，或諮詢專業顧問。公司未來業績受多項不確定因素影響，包括市場環境、監管審批及競爭狀況等。
